TBG Diagnostics (TDLAF) Stock Price, News & Analysis

Company Overview

TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, instruments, and services in Taiwan and China. It provides ExProbe HLA and HPA kits for human leukocyte antigen (HLA) and human platelet antigens (HPA) allele genotyping, which uses real time polymerase chain reaction (PCR) techniques with sequence specific primers and probes; Morgan SSP HLA kits for determining HLA alleles using PCR techniques with sequence specific primers; HLAssure SBT HLA Kits for transplantation donor selection; and AccuType SBT analysis software to analyze sequences from all ab1 based files. The company also offers Morgan SSPal HLA Typing Analysis Software, a gel result interpretation software; HLA typing services that offer low to high resolution using PCR fragment analysis (SSP) and DNA sequencing (SBT); QPCR Q6000, a six-channel real time PCR instrument; QzNGS NGS that provides high resolution HLA genotyping; and COVID-19 testing kits. It serves clinical labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 is based in Greenslopes, Australia.

Key Stats

• Today's Range: $0.04 to $0.13
• 50-Day Range: $0.04 to $0.04
• 52-Week Range: $0.01 to $0.13
• Volume: 3,200 shs
• Average Volume: 6,655 shs
• Market Capitalization: $2.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TDLAF Stock Analysis - Frequently Asked Questions

How have TDLAF shares performed this year?

TBG Diagnostics' stock was trading at $0.0430 at the beginning of 2025. Since then, TDLAF stock has increased by 0.0% and is now trading at $0.0430.
View the best growth stocks for 2025 here.

How do I buy shares of TBG Diagnostics?

Shares of TDLAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medicinals & Botanicals
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:TDLAF
• CIK: N/A
• Web: www.tbgbio.com
• Phone: 61 7 3088 7926
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $2.33 million
• Price / Sales: 1.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 55,290,000
• Free Float: N/A
• Market Cap: $2.38 million
• Optionable: Not Optionable
• Beta: -12.38